If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-10. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
== Development == Valve developed Half-Life 2 (2004) over six years using its new game engine, Source. Instead of beginning work on a full sequel, Valve decided to create a series of episodic sequels. The designer Robin Walker said the team had become comfortable with their tools, and wanted to capitalize on their experience instead of developing new technologies. Valve's president, Gabe Newell, said customers would be happier with a new Half-Life game delivered in a shorter time rather than waiting years for another "monolithic product". In April 2005, Valve announced the game under the working title Aftermath. The title Episode One was announced in February 2006. In May, Valve announced that Episode One would be the first in a trilogy of episodic games to be released over the following two years. Newell said he considered the trilogy the equivalent of Half-Life 3. According to Newell, whereas the original Half-Life (1998) saw the G-Man transform Freeman into his tool, and Half-Life 2 saw Freeman being used by G-Man, the episodes would see G-Man lose control. While the plots and dialogue of Half-Life and Half-Life 2 were written solely by Marc Laidlaw, the Half-Life 2 episodes were written by Laidlaw and the new employees Chet Faliszek and Erik Wolpaw. Valve's focus was character development, particularly that of Gordon's companion Alyx, who accompanies the player for most of Episode One. Walker said it was ironic that the player spends most of Half-Life 2 alone despite the themes of "characters and other people".
This approximation is convenient and applicable with little error in most applications having to deal with pools of hydrogen from natural processes. The maximum difference between the calculated delta (δ) value with the approximate and exact equations is given by the following equation:
Over the weekend following the introduction of new orders, calls for Ford's resignation over his handling of the COVID-19 crisis grew, In April 2021, Ford revealed that he had been in isolation following contact with one of his staffers, who had contracted COVID-19. Ford announced on April 30, 2021, that he had asked the federal government to stop international students from coming into the province in an effort to curb the third wave.
Pressure ulcers, also known as pressure sores, bed sores or pressure injuries, are localised damage to the skin and/or underlying tissue that usually occurs over a bony prominence as a result of usually long-term pressure, or pressure in combination with shear or friction. The most common sites are the skin overlying the sacrum, coccyx, heels, and hips, though other sites can be affected, such as the elbows, knees, ankles, back of shoulders, or the back of the cranium. Pressure ulcers occur due to pressure applied to soft tissue which results in completely or partially obstructed blood flow to the soft tissue. Shear is also a cause, as it can pull on blood vessels that feed the skin. Pressure ulcers most commonly develop in individuals who are not moving about, such as those who are on chronic bedrest or consistently use a wheelchair. It is widely believed that other factors can influence the tolerance of skin for pressure and shear, thereby increasing the risk of pressure ulcer development. These factors are protein-calorie malnutrition, microclimate (skin wetness caused by sweating or incontinence), diseases that reduce blood flow to the skin, such as arteriosclerosis, or diseases that reduce the sensation in the skin, such as paralysis or neuropathy. The healing of pressure ulcers may be slowed by a person's age, medical conditions (such as arteriosclerosis, diabetes or infection), smoking or medications such as anti-inflammatory drugs.
Sources: en.wikipedia.org
29 July – Prime Minister Rishi Sunak urges Mayor of London Sadiq Kahn to reconsider his plans to expand the Ultra Low Emission Zone, describing it as an "unnecessary extra tax". 30 July – Grime artist Stormzy and HSBC announce an extension of the Stormzy Scholarships scheme, with funding for a further 36 places for black students at Cambridge University. Each student will receive a £20,000 annual scholarship. 31 July – The National Education Union says that its members have voted to accept the UK government's 6.5% pay offer for teachers in England, with 86% of those voting in favour of the increase. Wild camping is to be allowed on Dartmoor once again after the National Park Authority wins a legal challenge against its suspension.
==== Crown ether-type CSP ==== Crown ethers, like cyclodextrin-type CSPs contain a chiral cavity. Crown ethers are immobilized on the silica surface to form chiral stationary phase. Crown ethers contain oxygen atoms within the cavity. The cyclic structure that contains apolar ethylene groups between oxygen forms hydrophobic inner cavity. Cram et al., introduced CSP based on chiral crown ethers and accomplished separation of amino acid. The crucial chiral recognition principle underlying crown ether-based enantiomer separation is based on the formation of numerous hydrogen bonds between the protonated primary amino group of the analyte and the ether oxygens of the crown structure. This structural requirement confines the application of crown ether-type CSPs to chiral compounds having primary amino groups adjoining the chiral centers, such as amino acids, amino acid derivatives. Progress in the field of crown ether-type CSPs have been reviewed.
With the invention of the Geiger gaseous ionization detector in 1913, which became the Geiger-Müller gaseous ionization detector in 1928 - named after the physicists Hans Geiger (1882-1945) and Walther Müller (1905-1979) - the individual particles or quanta of ionizing radiation could be detected and measured. Detectors developed later, such as proportional counters or scintillation counters, which not only "count" but also measure energy and distinguish between types of radiation, also became important for radiation protection. Scintillation measurement is one of the oldest methods of detecting ionizing radiation or X-rays; originally, a zinc sulfide screen was held in the path of the beam and the scintillation events were either counted as flashes or, in the case of X-ray diagnostics, viewed as an image. A scintillation counter known as a spinthariscope was developed in 1903 by William Crookes (1832-1919) and used by Ernest Rutherford (1871-1937) to study the scattering of alpha particles from atomic nuclei.
== Properties == The down hair of the vicuña used for the production of vicuña wool is, with an average hair diameter of 11–13.5 microns, one of the finest animal hairs. Only shahtoosh, the hair of the Tibetan antelope, is finer, with an average diameter of 8–13 microns. Among animal textile fibers, besides shahtoosh, only the various silks and byssus have a smaller fiber diameter. The surface structure of the fiber has scales as in sheep wool. The scale spacing is between 7 and 14 scale rings per 100 microns. The cell arrangement of the fiber is bilateral in transmission electron microscopy (as also in guanaco hair), while it is disordered in llama and alpaca. In addition, vicuña wool can also be identified by mass spectrometry.
=== Rail freight === South Africa has a longer rail network than all other Sub-Saharan African countries combined, at a total length of 23,000 km. Its network also features most of the double track rail in the region. State-owned Transnet Freight Rail is one of the largest players in the region. Approximately 15% of SA's land freight moves by rail. As of 2026, South Africa has three "Bulk Mineral Rail Corridors", which are dedicated heavy haul lines for export minerals. These routes, which total 2,241km, are:
Sources: en.wikipedia.org
=== 1950–60s === After the war, some of the inventions found new applications. The first transistor radio was released in 1954, and its manufacturing process made use of vacuum pumps. The first integrated circuit or "chip" came to the market at the end of the 1950s, and vacuum pumps again played an important role in their production. These early inventions were Edwards' first steps into the electronics and semiconductors industry, which is to this day the company's biggest market. Chips became increasingly small throughout the decades, increasing the importance of vacuum purity.
== Creation and different nominations == 1943 - 1947 : creation of the 9th Colonial Infantry Division (French: 9e Division d'Infanterie Coloniale, 9e D.I.C) 1963 - 1976 : designated as 9th Brigade (French: 9e Brigade, 9eB) 1976 - 1999 : designated as 9th Marine Infantry Division (French: 9e Division d'Infanterie de Marine, 9e D.I.Ma) 1999 - 2013 : designated as 9th Light Armoured Marine Brigade (French: 9e Brigade Légère Blindée de Marine, 9e B.L.B.Ma) 2013–present : designated as 9th Marine Infantry Brigade (French: 9e Brigade d'Infanterie de Marine, 9e B.I.Ma)
ribonucleotide reductase (RNR) Also ribonucleoside diphosphate reductase. An enzyme which catalyzes the formation of deoxyribonucleotides via the reductive dehydroxylation of ribonucleotides, specifically by removing the 2' hydroxyl group from the ribose ring of ribonucleoside diphosphates (rNDPs). RNR plays a critical role in regulating the overall rate of DNA synthesis such that the ratio of DNA to cell mass is kept constant during cell division and DNA repair.
A substrate (quartz, silicon, stainless steel, carbon fibers, etc.) is coated with a catalytic metal (Fe, Co, Ni) layer. Typically that layer is iron and is deposited via sputtering to a thickness of 1–5 nm. A 10–50 nm underlayer of alumina is often also put down on the substrate first. This imparts controllable wetting and good interfacial properties. When the substrate is heated to the growth temperature (~600 to 850 °C), the continuous iron film breaks up into small islands with each island then nucleating a carbon nanotube. The sputtered thickness controls the island size and this in turn determines the nanotube diameter. Thinner iron layers drive down the diameter of the islands and drive down the diameter of the nanotubes grown. The amount of time the metal island can sit at the growth temperature is limited as they are mobile and can merge into larger (but fewer) islands. Annealing at the growth temperature reduces the site density (number of CNT/mm2) while increasing the catalyst diameter. The as-prepared carbon nanotubes always have impurities such as other forms of carbon (amorphous carbon, fullerene, etc.) and non-carbonaceous impurities (metal used for catalyst). These impurities need to be removed to make use of the carbon nanotubes in applications.
One of the few studies that looked at the influence of hormones on human bonding compared a control group with participants who had recently fallen in love. There were no differences for most of the hormones measured, including LH, estradiol, progesterone, DHEAS, and androstenedione. Testosterone and FSH were lower in men who had recently fallen in love, and there was also a difference in blood cortisol for both sexes, with higher levels in the group that was in love. These differences disappeared after 12–28 months and may reflect the temporary stress and arousal of a new relationship.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.